risperidone / Generic mfg. - LARVOL DELTA

Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole (clinicaltrials.gov) - P4 | N=31 | Completed | Sponsor: Vanderbilt University Medical Center | Recruiting ➔ Completed | N=350 ➔ 31

Enrollment change • Trial completion • Autism Spectrum Disorder • Genetic Disorders

Trends in Antipsychotic Drug Use in the United States, 2000-2016. (PubMed, Pharmacy (Basel)) - "From 2000 to 2011, prochlorperazine and haloperidol were the first- and second-most prescribed typical APDs, respectively; haloperidol became the most administered antipsychotic of this class as of 2012. Quetiapine was the most administered atypical antipsychotic medication, followed by risperidone and olanzapine until 2014, after which olanzapine was the second-most administered atypical APD. There was a notable decline in the use of atypical antipsychotics medications between 2005 and 2008, which may reflect the impact of the Food and Drug Administration's warnings and the American Diabetes Association's consensus position, but only for a short time. The usage patterns observed in this study support existing evidence of substantial off-label use of antipsychotic drugs in the US."

Journal • CNS Disorders • Diabetes • Metabolic Disorders

Delirium in cardiovascular medicine. (PubMed, Eur Heart J) - "Pharmacologic treatment is reserved for select cases; dexmedetomidine shows benefits in intensive care unit settings, while antipsychotics like quetiapine and risperidone may be used cautiously. The present state-of-the-art review summarizes the current literature on the epidemiology, mechanisms, clinical manifestations, diagnosis, prevention, and treatment of delirium in cardiovascular medicine. By integrating findings and interdisciplinary expert discussions from interventional cardiology, cardiac surgery, and psychiatry, it aims to define the unique vulnerability of this patient population, highlight critical knowledge gaps, and lay the foundation for developing targeted, evidence-based management strategies."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Critical care • Inflammation • Psychiatry • Vascular Neurology

Consensus document on the treatment of insomnia in patients with autism spectrum disorder under 18 years of age. (PubMed, An Pediatr (Engl Ed)) - "The document describes diagnostic tools for use before treatment initiation and provides recommendations for comprehensive management. The treatment of insomnia begins with sleep hygiene measures and personalized cognitive-behavioral therapies. In maintenance insomnia, if these are not sufficient, pediatric prolonged-release melatonin (PedPRM) is recommended as the first-line drug, starting with a dose of 2mg/day and adjusting it to up to 10mg/day as needed. If the problems persist, alimemazine, risperidone or clonidine can be added, in that order, in a stepwise fashion. For early insomnia, immediate-release melatonin (IRM) is recommended, starting with a dose of 5mg/day and reducing it to up to 2mg/day if it is effective or increasing it to up to 7mg/day otherwise, or else PedPRM. The dosage should be reevaluated periodically in regular follow-up visits using sleep diaries."

Journal • Autism Spectrum Disorder • CNS Disorders • Genetic Disorders • Insomnia • Pediatrics • Sleep Disorder • Sleep Wake Cycle Disorder

Characteristics and predictors of antipsychotic medication off-label use among community-dwelling older people. (PubMed, Nord J Psychiatry) - "Risperidone (43%) and quetiapine (39%) were the most used APs off-label. Alternative treatments are needed to curb off-label AP use among community-dwelling older adults, given the high prevalence of cardiovascular disease and stroke. Monitoring guidelines are needed to promote safer prescribing practices."

Journal • Alzheimer's Disease • Asthma • Bipolar Disorder • Cardiovascular • Chronic Obstructive Pulmonary Disease • CNS Disorders • Diabetes • Epilepsy • Immunology • Mental Retardation • Metabolic Disorders • Mood Disorders • Psychiatry • Pulmonary Disease • Respiratory Diseases

Insomnia in children with autism spectrum disorder (PubMed, Medicina (B Aires)) - "The link between sleep problems and the central symptoms of ASD, along with their multiple associations with other health issues, demonstrates that addressing sleep problems from childhood improves physical and mental health, as well as cognitive and adaptive functioning. Medical treatment should follow a stepped algorithm, starting with pediatric longrelease melatonin (PRLM), followed by alimemazine, risperidone, and clonidine, depending on the patient's clinical response."

Journal • Review • Autism Spectrum Disorder • CNS Disorders • Genetic Disorders • Insomnia • Pediatrics • Sleep Disorder

Associations of common antipsychotic medications with weight gain in youth and adults: a target trial emulation study. (PubMed, J Psychiatr Res) - "Among 4 first-line antipsychotic medications, aripiprazole was associated with the greatest 6-month weight gain in adults and olanzapine was associated with the greatest 6-month BMIz increase in children/adolescents, though adherence was lower for olanzapine than other medications. Clinicians should consider these differences in weight gain when initiating antipsychotic medications."

Journal • CNS Disorders • Genetic Disorders

AADC ENZYME ACTIVITY AND PROTEIN LEVELS IN SERUM DO NOT DIFFERENTIATE DEMENTIA WITH LEWY BODIES FROM CONTROLS OR OTHER DEMENTIAS (ADPD 2026) - "Data for a limited number (n=7) of patients on dopamine-related medication showed a clear increase in AADC enzyme activity and protein levels during levodopa/carbidopa treatment, and a decrease in patients who received risperidone, a combined serotonin 5-HT2A and dopamine D2-receptor antagonist. Serum AADC enzyme activity showed a moderate-strong correlation with serum AADC protein levels. However, neither serum AADC enzyme activity nor AADC protein levels were suitable as biomarkers to detect DLB or to discriminate DLB from other types of dementia. Finally, dopaminergic medication had strong effects on serum AADC enzyme activity and protein levels in the small subset of patients using this medication."

Alzheimer's Disease • CNS Disorders • Dementia • Frontotemporal Lobar Degeneration • Lewy Body Disease • DRD2

AGITATION SEVERITY AND PSYCHOTROPIC USE IN DELIRIUM SUPERIMPOSED ON DEMENTIA: FINDINGS FROM THE DELDEM COHORT (ADPD 2026) - "Antipsychotic use was markedly increased: haloperidol (29.9% vs 12.4%; p<0.001), quetiapine (51.3% vs 34.0%; p<0.001), risperidone (9.7% vs 5.9%; p=0.036). Conclusions DSD is associated with heightened agitation and increased psychotropic exposure, underscoring safety concerns and the need for tailored non-pharmacological strategies."

Alzheimer's Disease • CNS Disorders • Dementia

Risperidone-induced ischemic priapism in a psychiatric patient: a case report. (PubMed, Ann Med Surg (Lond)) - "Timely intervention is essential to reduce the risk of irreversible complications such as erectile dysfunction. Patient counseling on this rare but serious adverse effect may be warranted when initiating or restarting antipsychotic therapy."

Journal • CNS Disorders • Erectile Dysfunction • Pain • Psychiatry

Copy-number loss of 17p11.2 with a TMEM127 pathogenic variant: a unique case of combined Smith-Magenis, Birt-Hogg-Dubé, and Hereditary Paraganglioma-Pheochromocytoma syndromes. (ACMG 2026) - "Treatment and Management Current medications are metformin, losartan, simvastatin, risperidone, haloperidol, and biperiden, as well as continuous CPAP therapy. Conclusion We report a patient carrying a likely de novo 17p11.2 microdeletion involving RAI1 , FLCN , and TNFRSF13B , together with a pathogenic heterozygous TMEM127 variant, resulting in combined features of Smith-Magenis, Birt-Hogg-Dubé, and Hereditary Paraganglioma-Pheochromocytoma syndromes. This case underscores the need for an integrated genotype-phenotype interpretation and a coordinated clinical approach through multidisciplinary management for the adequate care and counselling of patients with multiloci genetic conditions."

Clinical • CNS Disorders • Developmental Disorders • Diabetes • Dyslipidemia • Genetic Disorders • Hypertension • Infectious Disease • Kidney Cancer • Mental Retardation • Metabolic Disorders • Neuroendocrine Tumor • Obesity • Obstructive Sleep Apnea • Otorhinolaryngology • Renal Cell Carcinoma • Respiratory Diseases • Sleep Disorder • Solid Tumor • Type 2 Diabetes Mellitus • FLCN • RAI1 • TMEM127 • TNFRSF13B

OBSESSIVE-COMPULSIVE DISORDER: A CASE REPORT ABOUT CULTURAL AND RELIGIOUS BARRIERS TO TREATMENT (WRMC 2026) - "We report the case of a 31-year-old Hispanic man with no prior psychiatric history, though with a past psilocybin, methamphetamine, and cannabis use, who was referred for intrusive violent and sexual thoughts, including images of harming others...In Japan, he was prescribed Sulpiride 50 mg and Estazolam 2 mg once daily, with minimal relief...He was started on Clonazepam 1 mg nightly, Fluoxetine 40 mg daily, and Risperidone 0.5 mg twice daily...Fluvoxamine 50 mg daily was initiated but self-discontinued due to palpitations...A sensitive, multidisciplinary approach that respected the patient's worldview while maintaining therapeutic alliance proved essential for adherence and improvement. Awareness of these barriers may guide clinicians in tailoring interventions that address both psychiatric symptoms and the patient's cultural context."

Case report • Clinical • Depression • Mood Disorders • Obsessive-Compulsive Disorder • Suicidal Ideation

Atypical Antipsychotics and Metabolic Dysfunction-Associated Steatotic Liver Disease in Children and Adolescents: A Systematic Review. (PubMed, Int J Psychiatry Med) - "Shedlock et al found increased obesity related risks in children with autism spectrum disorder; Kumra et al observed risperidone induced hepatotoxicity; and Mouzaki et al linked psychotropic use with more severe MASLD. Meta-analysis showed a small and statistically insignificant positive association between AAP and MASLD, with significant heterogeneity among studies, indicating a need for careful interpretation of results. Risk of bias ratings varied from fair to good.ConclusionThese findings will serve as a foundation for future studies, assist in devising interventions, and may help to reform clinical guidelines for using AAP in children and adolescents to ensure patient safety."

Journal • Review • Autism Spectrum Disorder • CNS Disorders • Fibrosis • Gastroenterology • Genetic Disorders • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Pediatrics

Trends in Atypical Antipsychotic Use Among Children and Adolescents With Depressive Disorders in Korea. (PubMed, J Korean Med Sci) - "The use of AAPs has progressively increased among Korean children and adolescents with depressive disorders, particularly among those with psychiatric comorbidities. Further studies are needed to establish safer and more evidence-based AAP treatments for depressive disorders in children and adolescents."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Recent Advances in Pharmacological Management of Autism: A Narrative Review. (PubMed, Cureus) - "Medications, including US Food and Drug Administration (FDA)‑approved antipsychotics such as risperidone and aripiprazole, are used to manage comorbid irritability and aggression, stimulants and non‑stimulants (e.g., methylphenidate, atomoxetine, clonidine, guanfacine) to treat ADHD-like symptoms, and melatonin for sleep disturbances. Other off‑label agents like selective serotonin reuptake inhibitor (SSRIs) for anxiety/obsessive compulsive disorder (OCD), anticonvulsants or mood stabilizers for mood dysregulation. Emerging compounds such as intranasal oxytocin and N‑acetylcysteine are under investigation but have not yet been formally approved. The future of ASD care hinges on the development of objective, biologically based diagnostic tools ranging from EEG and neuroimaging biomarkers to proteomic and metabolomic panels that could enable early, precise identification and guide personalized treatment strategies."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Depression • Epilepsy • Genetic Disorders • Immunology • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry • Sleep Disorder

A case of diverse psychiatric and functional impairments following immune checkpoint inhibitor therapy. (PubMed, PCN Rep) - "A 64-year-old man with Stage IV gastric cancer receiving nivolumab developed impaired consciousness, delusions, and dissociative behavior, and reduced instrumental activities of daily living during and after ICI therapy...Steroid pulse therapy and antipsychotics (risperidone, later olanzapine) improved symptoms...In patients undergoing ICI therapy, new-onset psychiatric symptoms should raise suspicion for irAEs. Timely multidisciplinary intervention is essential for accurate diagnosis and effective symptom management."

Checkpoint inhibition • Journal • Alzheimer's Disease • CNS Disorders • Dementia • Gastric Cancer • Oncology • Psychiatry • Solid Tumor

Use of antipsychotics in children and adolescents in Spain, 2015-2023: a real-world, population-based study. (PubMed, Span J Psychiatry Ment Health) - "AP prescriptions and patients treated among Spanish youth increased significantly between 2015 and 2023, with notable differences by age and sex. While total CED rose, treatment intensity per patient remained relatively stable. Future studies should investigate the clinical indications for these prescriptions as well as the outcomes associated with AP use in children and adolescents."

Journal • Real-world evidence • CNS Disorders

CLOZAPINE Response in Biotype-1 (clinicaltrials.gov) - P4 | N=524 | Recruiting | Sponsor: University of Texas Southwestern Medical Center | Trial primary completion date: Dec 2025 ➔ Apr 2026

Trial primary completion date • Bipolar Disorder • CNS Disorders • Psychiatry • Schizophrenia

Inpatient prescribing trends and differences in drug acquisition costs of long-acting injectable subcutaneous risperidone versus paliperidone palmitate: A single-center medication use evaluation. (PubMed, Ment Health Clin) - "Literature comparing differences in efficacy of inpatient initiation of long-acting paliperidone palmitate once monthly (PP1M) and subcutaneous risperidone long acting-injectable (SC-RLAI) is currently limited and inconclusive. Inpatient institutions may have an opportunity to decrease drug costs by switching from PP1M to SC-RLAI1M as a formulary-preferred medication when appropriate. However, administrators should consider institution-specific costs as well as product availability for patients after discharge."

Journal

Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use (clinicaltrials.gov) - P2 | N=64 | Active, not recruiting | Sponsor: Lone Baandrup | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2025 ➔ Mar 2026 | Trial primary completion date: Jun 2025 ➔ Nov 2025

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry

Pharmacologic treatment of tics and Gilles de la Tourette syndrome. (PubMed, Handb Clin Neurol) - "The strongest evidence supports the use of dopamine receptor antagonists, particularly atypical antipsychotics such as aripiprazole and risperidone. However, other agents - including α-2 adrenergic agonists, vesicular monoamine transporter 2 inhibitors, and topiramate - also play an important role in treatment strategies. Pharmacologic management of GTS should be individualized, taking into account symptom severity, functional impact, and the risk-benefit profile of each therapeutic option."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Mood Disorders • Movement Disorders • Obsessive-Compulsive Disorder • Psychiatry • Tourette Syndrome

A Multicentre, 4-Year Mirror-Image Study Comparing the Effectiveness of Long-Acting Injectable Antipsychotics in the Treatment of Bipolar Disorder: Results From the LAICO Study. (PubMed, Bipolar Disord) - "Study findings suggest that long-acting antipsychotics such as A1M, PP1M, and particularly PP3M are associated with high retention and lower hospitalisation rates after 2 years of treatment in patients with BD."

Clinical • Journal • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

Olanzapine in the treatment of schizophrenia in adolescents - mechanisms of action and therapeutic efficacy. (PubMed, Psychiatr Pol) - "Olanzapine is effective in adolescent psychosis and mania but carries substantial metabolic liability. Given no clear efficacy advantage over other SGAs, it is best positioned as a second-line agent in youth, with preference for monotherapy, cautious dosing, and stringent metabolic monitoring. Evidence for benefits on negative and cognitive symptoms in adolescents remains limited."

Journal • Review • Bipolar Disorder • CNS Disorders • Depression • Dyslipidemia • Metabolic Disorders • Mood Disorders • Pediatrics • Psychiatry • Schizophrenia

The effect of adjuvant treatment in obsessive compulsive disorder patients: A systematic review and meta-analysis. (PubMed, J Family Med Prim Care) - "Meta-analysis of memantine suggested statistically insignificant (P value = 0.06) reduction in Y-BOCS score [SMD: -1.02 (-2.12, 0.08)], whereas meta-analysis of risperidone suggested statistically significant (P value = 0.03) reduction in Y-BOCS score [SMD: -0.38 (-0.74, -0.02)]. Risperidone plays a significant role in reduction of Y-BOCS score in OCD patients, whereas memantine does not show a significant effect in reducing the Y-BOCS score in OCD patients."

Journal • Retrospective data • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry

Effectiveness of Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics in People With Bipolar Disorder: A Systematic Review and Meta-Analysis of Observational Studies: Efficacité des antipsychotiques injectables à action prolongée par rapport aux antipsychotiques oraux chez les personnes atteintes de troubles bipolaires : revue systématique et méta-analyse d' (PubMed, Can J Psychiatry) - "LAIs were not significantly superior to OAPs in high-quality cohort studies (k = 3, P = 0.78) but in those adjusted for >5 factors (k = 2, RR = 0.56, 95% CI = 0.37;0.84, P = 0.006) nor in high-quality mirror-image studies (k = 2, P = 0.38), but in each second-generation antipsychotic-LAIs study (aripiprazole-LAI: k = 2, risperidone-LAI: k = 1) (k = 3, RR = 0.40, 95% CI = 0.20;0.80, P = 0.03). Tolerability outcomes were missing, and GRADE certainty-of-evidence was "low" to "very low".DiscussionLAIs were superior versus OAPs in preventing relapse/hospitalisation in cohort and mirror-image studies, in the latter particularly for mania-related outcomes. More robust mirror-image and controlled cohort studies are needed to better assess the effectiveness and tolerability of LAI antipsychotics in BD."

Journal • Observational data • Retrospective data • Review • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry